CAMBRIDGE, MA, October 12, 2022 - ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a clinical provider conference. The conference will focus on the broad array of clinical trial technologies and provider capabilities. The technology will be presented at the OCT New England Conference in Boston, Massachusetts on October 12-13, 2022.
About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with sufficient expression of the peptide's target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
To learn more about Andarix, please visit www.andarix.com.
Contact Information
Chris Adams
Andarix Pharmaceuticals
Cambridge, MA
USA
Voice: 617-957-9858
